Phase 2 N=123 A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) — 166; 171 Days — p=0.589
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=55 Open Label Extension to Bridging Study CTBM100C2303
Pseudomonas Aeruginosa · Cystic Fibrosis
Primary: Percentage of Participants With Adverse Events (AEs) — 47.3 percentage of participants
N/A N=113 HRV Biofeedback in Pain Patients
Chronic Neuromuscular Pain
Primary: Pain Interference Rating, Measured With the Brief Pain Inventory (BPI) — 7.2; 7.4; 6.2; 6.9 score on a scale — p=<0.01
Early Phase 1 N=50 Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Primary: Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) — 53.6; 42.7 units on a scale — p=0.87
N/A N=1,320 Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
COVID-19
Primary: Sensitivity, Specificity and Accuracy — 889; 106; 27; 20 Participants
Phase 3 N=432 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Cytokine Storm (Covid-19)
Primary: Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care — 34; 17 Participants — p=0.769
Phase 1 N=61 A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)
Ebola Disease · Immunisation
Primary: Number of Participants With Clinical Safety Laboratory Adverse Events — 2; 5; 4; 2 Participants
Phase 1 N=18 Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
Ulcerative Colitis
Primary: Number of Participants With Clinical Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0 — 2; 0…
Phase 2 N=19 Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
N/A N=269 Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
Chronic Pain · Intractable Pain
Primary: Mean Change in Pain From Baseline to 6 Months Post-permanent Implant, Assessed by the Numeric Rating Scale (NRS) — 7.6; 4.6; 3.0 score on a scale
Phase 3 N=474 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
ADHD
Primary: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale, 5th Edition (ADHD-RS-5) — -10.9; -16.6; -17.7 score on a scale — p=0.0004
Phase 2 N=18 Vidofludimus Calcium for Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis
Primary: Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels. — 3 Participants
Phase 3 N=333 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population — 69; 95 Number of…
Phase 2 N=155 A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
Hypertension
Primary: Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF) — -11.4; -13.1; -12.5; -18.7 mmHg
Phase 2 N=60 Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Spinal Cord Injury · Acute Spinal Cord Injury · Bone Loss
Primary: Percent Change in Bone Mass Density (BMD) in the Hip — -2.21; -12.82 percent change in bone mass density — p=0.05